Login to Your Account



Clinic Roundup


Monday, April 4, 2011
CorMedix Inc., of Bridgewater, N.J., reported an interim analysis of a Phase II study of CRMD001 (deferiprone) in preventing contrast-induced acute kidney injury (CI-AKI) in high-risk patients who have chronic kidney disease. CRMD001 appears to have a favorable safety profile, according to a blinded review of the data. So far, 38 patients have been enrolled at six U.S. sites, with five reported serious adverse events that are not considered to be drug-related.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription